Cytosorbents (CTSO) Retained Earnings (2010 - 2026)

Cytosorbents' Retained Earnings history runs 17 years deep, the most recent figure standing at -$317.3 million for Q1 2026.

• Quarterly Retained Earnings fell 21037.16% year-over-year to -$317.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$317.3 million (down 21037.16% YoY) and the FY2025 annual result came in at $321.0 million, up 7449.95% from the prior year.
• Retained Earnings was -$317.3 million for Q1 2026 at Cytosorbents, down from $321.0 million in the prior quarter.
• Across five years, Retained Earnings topped out at $321.0 million in Q4 2025 and bottomed at -$317.3 million in Q1 2026.
• A 5-year average of $78.5 million and a median of $6.2 million in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings jumped 19351.7% — and 2026, when it plunged 21037.16%.
• Cytosorbents' Retained Earnings stood at -$254.0 million in 2022, then surged by 100.21% to $529321.0 in 2023, then jumped by 703.29% to $4.3 million in 2024, then surged by 7449.95% to $321.0 million in 2025, then slumped by 198.85% to -$317.3 million in 2026.
• Business Quant data shows CTSO's Retained Earnings at -$317.3 million in Q1 2026, $321.0 million in Q4 2025, and -$306.7 million in Q3 2025.